SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Sternberg SS. Cross-striated fibrils and other ultrastructural alterations in glomeruli of rats with daunomycin nephrosis. Lab. Invest. 1970 Jul; 23 (1): 3951.
  • 2
    Bucciarelli E, Binazzi R, Santori P, Vespasiani G. [Nephrotic syndrome in rats due to adriamycin chlorhydrate]. Lav. Ist. Anat. Istol. Patol. Univ. Studi Perugia 1976; 36 (2): 5369.
  • 3
    Chen A, Sheu LF, Ho YS et al. Experimental focal segmental glomerulosclerosis in mice. Nephron 1998; 78: 44052.
  • 4
    Burke JF Jr, Laucius JF, Brodovsky HS, Soriano RZ. Doxorubicin hydrochloride-associated renal failure. Arch. Intern. Med. 1977; 137: 3858.
  • 5
    Pippin JW, Brinkkoetter PT, Cormack-Aboud FC et al. Inducible rodent models of acquired podocyte diseases. Am. J. Physiol. Renal Physiol. 2009 Feb; 296 (2): F21329.
  • 6
    Weiss RB. The anthracyclines: Will we ever find a better doxorubicin? Semin. Oncol. 1992; 19: 67086.
  • 7
    Adriamycin [database on the Internet]. Health Communication Network. 2010 [Cited 11 August 2010.] Available from URL: http://www.pfizer.com.au/DisplayPI.aspx?PDFDocumentID=2d46c4ce-308d-4b9f-8ac4-106563185b48.
  • 8
    Yesair DW, Schwartzbach E, Shuck D, Denine EP, Asbell MA. Comparative pharmacokinetics of daunomycin and adriamycin in several animal species. Cancer Res. 1972; 32: 117783.
  • 9
    Cao Q, Wang Y, Zheng D et al. IL-10/TGF-beta-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis. J. Am. Soc. Nephrol. 2010; 21: 93342.
  • 10
    Lee VW, Wang Y, Qin X et al. Adriamycin nephropathy in severe combined immunodeficient (SCID) mice. Nephrol. Dial. Transplant. 2006 Nov; 21 (11): 32938.
  • 11
    Jeansson M, Bjorck K, Tenstad O, Haraldsson B. Adriamycin alters glomerular endothelium to induce proteinuria. J. Am. Soc. Nephrol. 2009; 20: 11422.
  • 12
    Hayashi K, Sasamura H, Ishiguro K, Sakamaki Y, Azegami T, Itoh H. Regression of glomerulosclerosis in response to transient treatment with angiotensin II blockers is attenuated by blockade of matrix metalloproteinase-2. Kidney Int. 2010; 78: 6978.
  • 13
    Heikkila E, Juhila J, Lassila M et al. {beta}-Catenin mediates adriamycin-induced albuminuria and podocyte injury in the adult mouse kidneys. Nephrol Dial Transplant. 2010; 8: 243746. (Epub ahead of print).
  • 14
    Deelman LE, Navis G, de Boer E, Wietses M, de Zeeuw D, Henning RH. Role of proteinuria in the regulation of renal renin-angiotensin system components in unilateral proteinuric rats. J. Renin Angiotensin Aldosterone Syst. 2003 Mar; 4 (1): 3842.
  • 15
    Mandelbaum A, Podjarny E, Bernheim J, Green J, Rathaus M. Role of thromboxane in the altered vascular reactivity of pregnant rats with adriamycin nephropathy. Nephrol. Dial. Transplant. 1999 May; 14 (5): 11248.
  • 16
    Cheng H, Fan X, Guan Y, Moeckel GW, Zent R, Harris RC. Distinct roles for basal and induced COX-2 in podocyte injury. J. Am. Soc. Nephrol. 2009 Sep; 20 (9): 195362.
  • 17
    Rangan GK, Wang Y, Harris DC. Induction of proteinuric chronic glomerular disease in the rat (Rattus norvegicus) by intracardiac injection of doxorubicin hydrochloride. Contemp. Top. Lab. Anim. Sci. 2001 Sep; 40 (5): 449.
  • 18
    Porpaczy P, Schmidbauer CP, Georgopoulos A, Rameis H. Concentrations of doxorubicin in renal interstitial fluid after peripheral intravenous and intrarenal artery infusion in dogs. J. Urol. 1984; 131: 16972.
  • 19
    Johansen PB. Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse. Cancer Chemother. Pharmacol. 1981; 5: 26770.
  • 20
    De Boer E, Navis G, Tiebosch AT, De Jong PE, De Zeeuw D. Systemic factors are involved in the pathogenesis of proteinuria-induced glomerulosclerosis in adriamycin nephrotic rats. J. Am. Soc. Nephrol. 1999 Nov; 10 (11): 235966.
  • 21
    Ochodnicky P, Henning RH, Buikema H et al. Renal endothelial function and blood flow predict the individual susceptibility to adriamycin-induced renal damage. Nephrol. Dial. Transplant. 2009 Feb; 24 (2): 41320.
  • 22
    Sakemi T, Ohtsuka N, Tomiyoshi Y, Morito F. Sex difference in progression of adriamycin-induced nephropathy in rats. Am. J. Nephrol. 1996; 16: 54047.
  • 23
    Wang Y, Wang YP, Tay YC, Harris DC. Progressive adriamycin nephropathy in mice: Sequence of histologic and immunohistochemical events. Kidney Int. 2000; 58 (4): 1797804.
  • 24
    Mahajan D, Wang Y, Qin X et al. CD4+CD25+ regulatory T cells protect against injury in an innate murine model of chronic kidney disease. J. Am. Soc. Nephrol. 2006; 17 (10): 273141.
  • 25
    Wang Y, Feng X, Bao S et al. Depletion of CD4(+) T cells aggravates glomerular and interstitial injury in murine adriamycin nephropathy. Kidney Int. 2001 Mar; 59 (3): 97584.
  • 26
    Wang Y, Mahajan D, Tay YC et al. Partial depletion of macrophages by ED7 reduces renal injury in Adriamycin nephropathy. Nephrology (Carlton) 2005; 10: 47077.
  • 27
    Wang Y, Wang YP, Zheng G et al. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int. 2007; 72: 29099.
  • 28
    Wang Y, Cao Q, Zheng G et al. By homing to the kidney, activated macrophages potently exacerbate renal injury. Am. J. Pathol. 2008 Jun; 172 (6): 14919.
  • 29
    Pedrycz A, Wieczorski M, Czerny K. Histological and histochemical assessment of the effects of a single dose adriamycin on fetal rat kidney. Acta Histochem. 2005; 107: 21520.
  • 30
    Podjarny E, Bernheim J, Rathaus M, Pomeranz A, Tovbin D, Shapira J. Adriamycin nephropathy: A model to study effects of pregnancy on renal disease in rats. Am. J. Physiol. 1992 Oct; 263 (4 Pt 2): F71115.
  • 31
    Podjarny E, Losonczy G, Baylis C. Animal models of preeclampsia. Semin. Nephrol. 2004; 24: 596606.
  • 32
    Pomeranz M, Podjarny E, Bernheim J, Pomeranz A, Rathaus M, Green J. Effect of recurrent pregnancies on the evolution of adriamycin nephropathy. Nephrol. Dial. Transplant. 1995; 10: 204953.
  • 33
    Mortell A, Fourcade L, Solari V, Puri P. Bilateral megaureters in the Adriamycin rat model. Pediatr. Surg. Int. 2005; 21: 21216.
  • 34
    Lee VW, Wang YM, Wang YP et al. Regulatory immune cells in kidney disease. Am. J. Physiol. Renal Physiol. 2008 Aug; 295 (2): F33542.
  • 35
    Watson D, Zheng G, Wu H et al. CCL2 DNA vaccine to treat renal disease. Int. J. Biochem. Cell Biol. 2009; 41: 72932.
  • 36
    Wang Y, Wang YP, Tay YC, Harris DC. Role of CD8(+) cells in the progression of murine adriamycin nephropathy. Kidney Int. 2001 Mar; 59 (3): 9419.
  • 37
    Zheng G, Zheng L, Wang Y et al. NK cells do not mediate renal injury in murine adriamycin nephropathy. Kidney Int. 2006; 69: 115965.
  • 38
    Wu H, Wang YM, Wang Y et al. Depletion of gammadelta T cells exacerbates murine adriamycin nephropathy. J. Am. Soc. Nephrol. 2007 Apr; 18 (4): 118089.
  • 39
    Wang YM, Zhang GY, Wang Y et al. Foxp3-transduced polyclonal regulatory T cells protect against chronic renal injury from adriamycin. J. Am. Soc. Nephrol. 2006 Mar; 17 (3): 697706.
  • 40
    Qin XH, Lee VW, Wang YP et al. A protective role for programmed death 1 in progression of murine adriamycin nephropathy. Kidney Int. 2006; 70: 124450.
  • 41
    Rangan GK, Wang Y, Harris DC. Pharmacologic modulators of nitric oxide exacerbate tubulointerstitial inflammation in proteinuric rats. J. Am. Soc. Nephrol. 2001 Aug; 12 (8): 1696705.
  • 42
    Cao Q, Wang Y, Zheng D et al. IL-10/TGF-{beta}-Modified Macrophages Induce Regulatory T Cells and Protect against Adriamycin Nephrosis. J. Am. Soc. Nephrol. 2010; 6: 93342.
  • 43
    Zheng G, Wang Y, Xiang SH et al. DNA vaccination with CCL2 DNA modified by the addition of an adjuvant epitope protects against ‘nonimmune’ toxic renal injury. J. Am. Soc. Nephrol. 2006 Feb; 17 (2): 46574.
  • 44
    Marshall CB, Krofft RD, Pippin JW, Shankland SJ. The CDK-inhibitor p21 is Pro-survival in Adriamycin(R)-Induced Podocyte Injury, in vitro and in vivo. Am. J. Physiol. Renal Physiol. 2009 (in press). doi:10.1152/ajprenal.00216.2009.
  • 45
    Kairaitis L, Wang Y, Zheng L, Tay YC, Harris DC. Blockade of CD40-CD40 ligand protects against renal injury in chronic proteinuric renal disease. Kidney Int. 2003 Oct; 64 (4): 126572.
  • 46
    Lee VW, Qin X, Wang Y et al. The CD40-CD154 co-stimulation pathway mediates innate immune injury in adriamycin nephrosis. Nephrol. Dial. Transplant. 2010; 3: 71730.
  • 47
    Ren Y, Sun W, Zhao Y, Ma Q, Wang Z. [Effect of Qufengtongluo recipe on expression of nephrin mRNA in adriamycin-induced nephropathy in rats]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2009; 34: 121623.
  • 48
    Kairaitis L, Wang Y, Tay YC, Harris DC. Murine FSGS is attenuated in CD40 knockout mice. Nephrology (Carlton) 2002; 7 (s3): A57.
  • 49
    Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB, Liu Y. Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J. Am. Soc. Nephrol. 2009 Sep; 20 (9): 19972008.
  • 50
    Zheng D, Cao Q, Sun Y et al. Regulatory Plasmacytoid Dendritic Cells Reduce Renal Injury in Murine Adriamycin Nephropathy. Nephrology (Carlton) 2009; 14 (s1): A17.
  • 51
    Magnasco A, Corselli M, Bertelli R et al. Mesenchymal stem cells protective effect in adriamycin model of nephropathy. Cell Transplant. 2008; 17 (10–11): 115767.
  • 52
    Yasuda K, Park HC, Ratliff B et al. Adriamycin nephropathy: A failure of endothelial progenitor cell-induced repair. Am. J. Pathol. 2010; 4: 168595.
  • 53
    Chen S, Fang Z, Zhu Z, Deng A, Liu J, Zhang C. Protective effect of sulodexide on podocyte injury in adriamycin nephropathy rats. J. Huazhong Univ. Sci. Technolog Med. Sci. 2009; 29: 71519.
  • 54
    Zeng WY, Chen L. [Protective effect of Galla chinensis apozema on adriamycin-induced nephropathy in rats]. Zhong Yao Cai 2009; 32: 12624.
  • 55
    Dabak DO, Kuloglu T, Ozercan MR. Effects of vitamin D3 (cholecalciferol) on adriamycin-induced nephrotoxicity. Ren. Fail. 2009; 31: 4005.
  • 56
    Zheng Z, Schmidt-Ott KM, Chua S et al. A Mendelian locus on chromosome 16 determines susceptibility to doxorubicin nephropathy in the mouse. Proc. Natl. Acad. Sci. USA 2005 Feb; 102 (7): 25027.
  • 57
    Liu T, Nishimura H, Matsuguchi T, Yoshikai Y. Differences in interleukin-12 and -15 production by dendritic cells at the early stage of Listeria monocytogenes infection between BALB/c and C57 BL/6 mice. Cell. Immunol. 2000; 202: 3140.
  • 58
    Chen X, Oppenheim JJ, Howard OM. BALB/c mice have more CD4+CD25+ T regulatory cells and show greater susceptibility to suppression of their CD4+CD25- responder T cells than C57BL/6 mice. J. Leukoc. Biol. 2005; 78: 11421.
  • 59
    Zheng Z. An Ancestral Haplotype Defines Susceptibility to Doxorubicin Nephropathy in the Laboratory Mouse. J. Am. Soc. Nephrol. 2006 Jun 21; 17 (7): 1796800.
  • 60
    Barbey MM, Fels LM, Soose M et al. Adriamycin affects glomerular renal function: Evidence for the involvement of oxygen radicals. Free Radic. Res. Commun. 1989; 7 (3–6): 195203.
  • 61
    Guo J, Ananthakrishnan R, Qu W et al. RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J. Am. Soc. Nephrol. 2008; 19: 96172.
  • 62
    Otaki Y, Miyauchi N, Higa M et al. Dissociation of NEPH1 from nephrin is involved in development of a rat model of focal segmental glomerulosclerosis. Am. J. Physiol. Renal Physiol. 2008 Nov; 295 (5): F137687.
  • 63
    Sadlier DM, Connolly SB, Kieran NE et al. Sequential extracellular matrix-focused and baited-global cluster analysis of serial transcriptomic profiles identifies candidate modulators of renal tubulointerstitial fibrosis in murine adriamycin-induced nephropathy. J. Biol. Chem. 2004 Jul; 279 (28): 2967080.
  • 64
    Lahouel M, Viotte G, Sumereau E, Morin JP, Fillastre JP. Haematotoxicity of doxorubicin and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and of their association in rats. Drugs Exp. Clin. Res. 1987; 13: 5939.
  • 65
    Llesuy SF, Arnaiz SL. Hepatotoxicity of mitoxantrone and doxorubicin. Toxicology 1990; 63: 18798.
  • 66
    Shug AL. Protection from adriamycin-induced cardiomyopathy in rats. Z. Kardiol. 1987; 76 (Suppl 5): 4652.